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Abstract:1p/19q (1p and/or 19q) deletions are prognostic factors in oligodendroglial tumors (OT) and predict better survival after both 
chemotherapy and radiotherapy. While studying 1p/19q status as a potential variable within multivariate prognosis models for OT, we 
have frequently encountered unknown 1p/19q status within our glioma sample database due to lack of paired blood samples for loss of 
heterozygosity (LOH) assay and/or failure to perform fluorescence in situ hybridization (FISH). We realized that a 1p and 19q deletion 
assay that could be reliably performed solely on tumor DNA samples would allow us to fill in these molecular biology data “holes”. 
We built recombinant DNA with fragments of the selected “marker” genes in 1p (E2F2, NOTCH2), and 19q (PLAUR) and “reference” 
genes (ERC2, SPOCK1, and SPAG16  ) and used it as quantification standard in real-time PCR to gain absolute ratios of marker/reference 
gene copy numbers in tumor DNA samples, thus called comparative quantitative PCR (CQ-PCR). Using CQ-PCR, we identified 1p and/
or 19q deletions in majority of pure low-grade oligodenroglioma (OG) tumors (17/21, 81%), a large portion of anaplastic oligodendro-
glioma (AO) tumors (6/15, 47%), but rarely found in mixed oligoastrcytomas (OA) tumors (1/8, 13%). These data are consistent with 
results of LOH and FISH assays generally reported for these tumor types. In addition, 15 out 18 samples showed concordant results 
between FISH and CQ-PCR. We conclude that CQ-PCR is a potential means to gain 1p/19q deletion information, which prognostic and 
predictive values of CQ-PCR-derived 1p/19q status will be determined in a future study.
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Introduction
The current gold standard for the diagnosis of glioma 
relies  on  histological  examination  of  tumor  tissue; 
however molecular analyses have uncovered impor-
tant  genetic  abnormalities,  some  of  which  provide 
useful information pertaining to variations in patient’s 
overall survival and/or response to treatment. Among 
gliomas, deletion of 1p and 19q are associated with 
tumors with oligodendroglial components.1,2 1p and/or 
19q (1p/19q) deletions have been observed in up to 70% 
of oligodendrogliomas and 50% of mixed oligoastro-
cytomas (OA).3,4 In addition to their diagnostic rele-
vance, 1p/19q status is a predictive marker for overall 
improved outlook for patients with oligodendroglial 
tumors (OT).3–6 Several studies have suggested that the 
1p/19q status (co-deleted or not) predicts response of 
OT to radiation,7 chemotherapy,8–10 or combined.11,12
Due to the potential importance of 1p/19q status 
for patients with OT, several molecular methods have 
been standardized to detect this genetic abnormal-
ity in both clinical and basic research settings. The 
most commonly applied techniques to detect 1p/19q 
deletion  are  loss  of  heterozygosity  (LOH),13,14  and 
fluorescence in situ hybridization (FISH).15,16 LOH 
requires paired blood DNA from the same patient, 
which is not routinely collected by most university 
tissue banks. FISH detection of 1p/19q deletion is 
frequently employed in clinical laboratories, but is 
costly and requires highly experienced personnel to 
ensure accuracy and data standardization.
To date, the best means for incorporating 1p/19q 
data into clinical practice remains controversial. There 
is an urgent need for accurate prognostic tools (partic-
ularly if the prognostic variables predict therapeutic 
response), for life-planning purposes for patients and 
treatment planning purposes for clinicians. However, 
development  of  prognosis  models  for  gliomas  has 
been a challenge due to their relatively low incidence 
and greater variation in survival per patient within a 
given histology and grade.17 A good statistical percept 
for building a multivariable prognosis model is that 
we should have at least 10 events (deaths) for each 
candidate variable studied.18 Thus when possible all 
available tumor resource of OT should be utilized. 
However, as shown in a recent retrospective study of 
over 1000 WHO grade III OT, 38% of tumor samples 
were missing 1p or 19q data. As a result, these tumors 
were excluded from the study.12
To explore an accurate means of filling these 1p 
19q “data holes” independent of LOH or FISH via a 
test solely reliant on tumor sample DNA, we explored 
real-time PCR technology. We employed a standard-
based absolute real-time PCR concept in quantifying 
gene  expression,19  to  gain  absolute  ratios  of  DNA 
copy  numbers  of  marker  genes  in  1p  or  19q  and 
reference genes in relatively “stable” areas in chro-
mosomes, here referred as comparative quantitative 
PCR (CQ-PCR). Over the past decade, the regions of 
interest on 1p deletion have been mapped to 1p36.3, 
1p36.1-p36.2, and 1p34-p35, the region of interest in 
19q is located between 19q13.11 and 19q13.4,20,21 and 
current clinical FISH test probes are associated with 
1p36 and 19q13 regions.5,16,22 CAMTA1 and NOTCH2 
genes reside in1p36.31-p36.23 and 1p13–11, respec-
tively, with potential tumor suppression functions,23,24 
while E2F2 tumor suppressor gene resides in 1p36.
Thus, we selected these three genes to analyze for 
deletion of 1p in gliomas. We selected PLAUR resid-
ing in 19q13 to study DNA copy number variation 
(CNV) of 19q, for its well-studied function in glioma 
invasion. According to CGH, there are certain chro-
mosomes that typically remain unaltered during the 
course  of  glioma  tumorigenesis,  including  2q,  3p, 
5q, 8q, 12q and 21p.25–27 Hence three genes (ERC2, 
SPAG16  and  SPOCK1)  located  in  chromosomes 
3p14.3, 2q34 and 5q31, respectively, were selected 
as reference genes to determine CNV of the selected 
marker genes in 1p and 19q. We report a quantitative, 
sensitive, accurate, and relatively inexpensive assay 
for determining gene CNV in 1p/19q by real-time 
CQ-PCR that can be performed using only a few ng 
tumor DNA sample, independent of the need for LOH 
or FISH analysis.
Materials and Methods
glioma and paired blood dNA samples
Glioma  specimens  were  obtained  from  patients  in 
accordance with Institutional Review Board approval 
at  each  participating  institutions  (University  of 
  California, Irvine, USA and University of   Arkansas 
for  Medical  Sciences,  USA).  We  included  DNA 
samples from 44 OTs, 9 paired blood lymphocytes 
collected  from  patients  during  surgical  resection 
of their gliomas, and 14 glioblastoma multiformes 
(GBMs)  in  this  study.  Breaking  down  of  44  OT 
samples included in analysis are 21 WHO grade II detection of 1p19q deletion by quantitative PCR
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  oligodendroglioma  (OG),  8 WHO  Grade  II  mixed 
oligo-astrocytoma  (OA),  15  either WHO  grade  III 
anaplastic oligodendroglioma (AO) or WHO grade III 
anaplastic mixed oligo-astrocytoma (AOA). For each 
case,  histological  assessment  of  the  tumor  tissues 
were performed by the neuropathologists in the par-
ticipating institutes. All DNA samples were extracted 
from  frozen  glioma  specimens  using  DNeasy  kit 
(QIAGEN), and approximately 2 ng DNA in 10 mM 
Tris-HCl (pH 7.5) was used to run real time PCR for 
each gene.
Real-time CQ-PCR
CQ-PCR standard CQ-103 and 10X PCR primer mix 
for  selected  marker  genes  in  1p  (CAMTA1,  E2F2 
and NOTCH2), 19q (PLAUR) and reference genes 
(ERC2, SPAG16 and SPOCK1); and CQ-PCR stan-
dard CQ-108 and 10X PCR primer mix for NLGN4Y 
and the same set of reference genes are from Ziren 
Research (Irvine, CA). We run real-time PCR with 
Roche  Light-Cycler  real-time  PCR  instrument  2.0 
(Indianapolis, IN) in a capillary tubes with 4 µl of 
standard or sample DNA (0.5 ng/µl), 1 µl of 10X 
FAST-START DNA Master SYBR Green I enzyme 
mix (Roche, Indianapolis, IN), 1 µl of the 10 X primer 
mix, and 4 µl of water in standard program setting 
with  denature  temperature  set  at  62°C,  extension 
time 12 sec. A melting curve cycle was included for 
each run to endure no formation of primer dimer after 
45 cycles. Gene copy numbers were exported directly 
from real-time PCR program, which was based on the 
standard curve (R value .0.99), a regression curve 
of  the  “cycle”  numbers  of  four  diluted  standards 
when PCR reaching log amplification to their DNA 
quantifies (102, 103, 104, 105 copies). All genes were 
  quantified  at  least  twice  in  separate  runs,  to  show 
assay  reproduction  with  ,20%  standard  deviation 
(SD), then mean copy number of each gene was taken 
for analysis, by calculating the ratio of each marker to 
the reference gene.
FISh detection of 1p and 19q loss
Paraffin embedded tissue obtained following surgical 
resection of glioma from patients were sent to Mayo 
Clinic, Department of Lab Medicine and Pathology, 
Rochester, Minnesota, USA for performing FISH with 
test probes (1p36 and 19q13) and control probes (1q24 
and 19p13). FISH signals for each gene-specific FISH 
probes were assessed under fluorescence microscope 
and the ratio of the probes for 1p/1q and 19p/19q were 
enumerated in 100 non-overlapping nuclei. A normal 
ratio is considered 1.0 and any ratio ,0.80 is consid-
ered deletion of the region of interest.
Results
The principle of CQ-PCR as a modification of single-
copy-gene standard-based real time PCR is via using 
a multi-gene-containing recombinant DNA standard 
that allows determination of absolute ratios of marker 
to  reference  gene  copy  numbers  in  sample  DNA. 
A ratio of 1:1 between selected marker and reference 
genes in autosomal chromosomes is expected in nor-
mal cells while changes in this ratio in tumor DNA 
would suggest CNV, either deletion or amplification, 
in the studied gene of interest.
Considering  the  inherent  genome  instability  of 
cancer cells, we analyzed the stability of three refer-
ence genes in tumor samples and found amplification 
of SPAG16 in some OT. To mitigate this, we took the 
average of two ratios of ERC2 and SPOCK1 for most 
tumors. For other samples, the two reference gene 
ratios showing the most concordance were used to 
take a mean and SD.
With consideration of 10%–20% variation inher-
ited  with  real-time  PCR,  the  mean  values  of  the 
marker and reference ratio was taken for determi-
nation  of  deletion  (,0.8)  or  amplification  (.1.2), 
Shown in Table 1, there was a gain at the 1p marker 
gene CAMTA1 (1p36.31-23) in both GBM and OT, 
which were not found in other two 1p marker genes 
E2F2 (1p36) and NOTCH2 (1p13-p11). Thus aver-
age of these two 1p marker genes ratio to reference 
gene  were  taken  to  determine  1p  deletion  status 
(value  ,0.80  is  considered  1p  deleted).  Based  on 
the results from 67 samples, the mean (medium) of 
the SDs from different reference ratios for the four 
marker genes is 10%–15% (7%–9%), which supports 
our setting of cut-off-line of 0.8 or 1.2 in determining 
gene CNV from results of CQ-PCR.
Similarly, the ratio of DNA copy number between 
a gene in Y-chromosome and a gene in autosomal 
chromosome is expected to be 0.5 in a normal male 
diploid  genome  while  zero  in  female  DNA.  As 
shown in   Figure 1. CQ-PCR determination of abso-
lute ratio of two gene copy numbers have given rise 
to a ratio value of 0.4–0.5 in normal cells of male Chaturbedi et al
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Table 1. CQ-PCR-derived Mean (Sd) ratios of 1p/19 marker genes to each reference genes.
WHO Histology Tumor 1p36.31–23 
CAMTA1
1p36 
E2F2
1p13-p11 
NOTCH2,
Ave E2F2 
& NOTCH
19q13 
PLAUR
FIsH
1p 19q
IV gBM UCI-g22 2.0 (0.54) 0.5 (0.27) 1.1 (0.66) 0.8 0.6 (0.38) na na
IV gBM UCI-g24 1.0 (0.06) 0.8 (0.01) 1.0 (0.03) 0.9 0.5 (0.01) na na
IV gBM UCI-g25 0.9 (0.17) 1.0 (0.14) 1.2 (0.19) 1.1 0.7 (0.09) na na
IV gBM UCI-g26 2.6 (1.30) 0.7 (0.44) 1.0 (0.61) 0.9 0.6 (0.33) na na
IV gBM UCI-g27 1.3 (0.09) 1.0 (0.04) 1.1 (0.11) 1.1 0.8 (0.08) na na
IV gBM UCI-g28 1.9 (0.21) 1.3 (0.10) 1.2 (0.12) 1.2 0.9 (0.07) na na
IV gBM UCI-g29 1.2 (0.02) 0.9 (0.01) 1.1 (0.01) 1.0 0.6 (0.01) na na
IV gBM UCI-g30 0.9 (0.01) 1.0 (0.02) 1.0 (0.00) 1.0 0.7 (0.01) na na
IV gBM UCI-g31 0.9 (0.01) 0.9 (0.09) 1.2 (0.15) 1.1 1.0 (0.10) na na
IV gBM UCI-g32 1.2 (0.33) 1.2 (0.38) 1.4 (0.41) 1.3 0.8 (0.24) na na
IV gBM UCI-g33 2.4 (0.51) 1.4 (0.01) 1.4 (0.01) 1.4 1.0 (0.00) na na
IV gBM UCI-g34 1.5 (0.13) 0.9 (0.02) 0.9 (0.04) 0.9 0.5 (0.03) na na
IV gBM UCI-g35 1.7 (0.21) 1.5 (0.16) 0.9 (0.05) 1.2 1.3 (0.15) na na
IV gBM UCI-g36 1.0 (0.00) 0.9 (0.10) 1.2 (0.05) 1.0 0.7 (0.08) na na
III AoA UCI-o51 1.6 (0.27) 1.0 (0.22) 1.1 (0.18) 1.1 0.6 (0.11) na na
III Ao UCI-o11 2.9 (0.43) 0.9 (0.13) 1.1 (0.16) 1.0 1.2 (0.21) na na
III Ao UCI-o16 1.8 (0.42) 1.3 (0.30) 0.2 (0.04) 0.7 1.2 (0.30) na na
III Ao UCI-o15 0.5 (0.19) 0.2 (0.09) 0.3 (0.11) 0.3 0.4 (0.17) na na
III Ao UCI-o17 1.7 (0.24) 0.7 (0.10) 1.0 (0.15) 0.8 0.5 (0.06) na na
III Ao UCI-o19 3.3 (0.51) 1.6 (0.24) 0.2 (0.04) 0.9 0.7 (0.13) nml del
III Ao UCI-o20 1.2 (0.13) 1.2 (0.13) 0.9 (0.10) 1.1 1.4 (0.11) na na
III Ao UCI-o27 2.2 (0.17) 1.4 (0.10) 1.2 (0.10) 1.3 1.2 (0.12) nml nml
III Ao UCI-o32 0.9 (0.05) 1.0 (0.06) 1.0 (0.07) 1.0 0.8 (0.06) nml del
III Ao UCI-o35 1.0 (0.09) 1.0 (0.09) 0.8 (0.07) 0.9 0.9 (0.09) del del
III Ao UCI-o36 0.8 (0.05) 1.2 (0.08) 1.0 (0.07) 1.1 1.0 (0.08) del nml
III Ao UCI-o42 1.0 (0.28) 1.0 (0.26) 0.7 (0.19) 0.8 0.7 (0.21) del del
III Ao UCI-o52 1.2 (0.07) 0.9 (0.02) 1.1 (0.05) 1.0 0.8 (0.02) nml nml
III Ao UAMS-o1 1.2 (0.13) 0.8 (0.09) 1.2 (0.13) 1.0 0.6 (0.07) na na
III Ao UAMS-o7 2.4 (0.04) 1.0 (0.03) 1.0 (0.02) 1.0 1.2 (0.02) na na
II oA UCI-o26 1.0 (0.17) 1.0 (0.16) 1.1 (0.18) 1.0 0.8 (0.15) nml nml
II oA UCI-o31 1.2 (0.09) 0.7 (0.06) 0.9 (0.08) 0.8 0.9 (0.09) na na
II oA UCI o44 0.8 (0.02) 0.9 (0.01) 1.0 (0.01) 0.9 0.9 (0.00) na na
II oA UCI o46 0.9 (0.06) 0.9 (0.03) 1.1 (0.06) 1.0 0.9 (0.03) na na
II oA UCI o47 1.2 (0.13) 0.9 (0.07) 0.9 (0.09) 0.9 0.8 (0.06) nml nml
II oA UCI o50 0.8 (0.25) 1.5 (0.06) 1.6 (0.10) 1.6 1.4 (0.06) na na
II oA UAMS-o2 1.1 (0.07) 0.7 (0.05) 0.7 (0.04) 0.7 0.8 (0.05) na na
II oA UAMS-o3 1.3 (0.14) 1.1 (0.09) 1.1 (0.10) 1.1 0.9 (0.09) na na
II og UCI-o10 0.8 (0.05) 0.4 (0.02) 0.6 (0.03) 0.5 0.4 (0.03) na na
II og UCI-o12 0.6 (0.09) 0.1 (0.01) 0.1 (0.01) 0.1 0.2 (0.03) na na
II og UCI-o13 0.8 (0.06) 0.4 (0.03) 0.1 (0.01) 0.3 0.3 (0.03) na na
II og UCI-o14 1.2 (0.12) 0.7 (0.08) 0.8 (0.09) 0.8 0.5 (0.05) nml nml
II og UCI-o18 0.7 (0.11) 0.6 (0.10) 0.7 (0.11) 0.7 1.0 (0.12) nml nml
II og UCI-o21 1.6 (0.05) 0.9 (0.02) 0.2 (0.01) 0.6 0.6 (0.02) na na
II og UCI-o24 1.1 (0.09) 0.5 (0.05) 0.7 (0.06) 0.6 0.4 (0.04) del del
II og UCI-o28 0.7 (0.16) 1.1 (0.24) 1.1 (0.24) 1.1 1.5 (0.29) nml nml
II og UCI-o29 1.5 (0.10) 1.3 (0.09) 1.2 (0.08) 1.2 0.7 (0.07) nml nml
II og UCI-o34 0.7 (0.04) 0.8 (0.04) 0.9 (0.05) 0.9 1.2 (0.09) nml nml
II og UCI-o38 1.1 (0.02) 1.1 (0.02) 0.9 (0.02) 1.0 1.2 (0.03) nml nml
II og UCI-o37 1.1 (0.08) 0.8 (0.06) 0.6 (0.05) 0.7 0.6 (0.06) na na
II og UCI-o39 2.5 (0.18) 1.5 (0.11) 0.5 (0.04) 1.0 1.1 (0.08) na na
II og UCI-o41 0.9 (0.08) 0.6 (0.06) 0.6 (0.060 0.6 0.5 (0.05) del del
II og UCI-o43 0.8 (0.01) 0.5 (0.01) 0.7 (0.00) 0.6 0.5 (0.01) na na
II og UCI-o48 1.2.(0.29) 0.7 (0.15) 0.9 (0.20) 0.8 0.6 (0.12) nml nml
(Continued)detection of 1p19q deletion by quantitative PCR
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Table 1. (Continued)
WHO Histology Tumor 1p36.31–23 
CAMTA1
1p36 
E2F2
1p13-p11 
NOTCH2,
Ave E2F2 
& NOTCH
19q13 
PLAUR
FIsH
1p 19q
II og UAMS-o4 1.6 (0.32) 1.4 (0.19) 1.4 (0.29) 1.4 0.7 (0.14) na na
II og UAMS-o5 0.8 (0.06) 0.8 (0.04) 0.8 (0.07) 0.8 0.4 (0.04) na na
II og UAMS-o6 0.7 (0.02) 0.6 (0.01) 0.6 (0.02) 0.6 0.3 (0.01) na na
II og UAMS-o8 1.1 (0.04) 0.8 (0.03) 0.8 (0.03) 0.8 0.5 (0.02) na na
II og UAMS-o9 1.6 (0.25) 1.1 (0.13) 1.1 (0.19) 1.1 0.6 (0.09) na na
Concordance between CQ-PCR and FISh data 83% 78%
notes: Numbers in bold and highlighted with light grey color indicates deletion of the specified marker gene with ratio to the reference gene ,0.80; 
numbers highlighted with dark grey indicates amplification of the specified marker gene with ratio to the reference gene .1.20.
Abbreviations: na, not available; wt, wild type; nml, normal; del, deletion.
and zero in female between genes in Y-(NLGN4Y) 
and    autosomal  chromosomes,  while  1.0  between 
two autosomal genes (ERC2, PGCP, SPAG16 and 
SPOCK1). To control human error in managing the 
tissue bank, we first carried out CQ-PCR of NLGN4Y 
and the autosomal genes in 61 tumor and 9 paired 
blood DNA samples, and analyzed for concordance 
with gender information provided by each participat-
ing institute’s tissue bank. Out of total 70 DNA sam-
ples we identified 3 tumor samples with conflicting 
information between gender-associated gene in DNA 
and gender information of the patients, which were 
excluded from this study.
Blood sample is generally considered to be nor-
mal, in terms of mutations and allelic loss or ampli-
fication in the tumor sample. It is the reference used 
by loss of heterozygosity assay (LOH) for detect-
ing loss of a microsatellite allele. In our CQ-PCR, 
we  selected  single  copy  protein-coding  gene  for 
both marker and reference genes, detected the copy 
  numbers of each, and compared relative difference in 
quantity. If there is deletion or amplification of a gene 
that is   associated with tumor, it normally should not 
occur in normal lymphocyte. Our CQ-PCR detected 
deletions of 1p (E2F2, NOTCH2) and 19q (PLAUR) 
markers in 5/9 OT but none in the paired blood DNA 
samples;  results  for  6  tumor  DNA  samples  with 
their paired blood DNA 1p and 19q were shown in 
  Figure 2. CAMTA1 was deleted in two and amplified 
in other two of the the six OT, but not in the paired 
blood DNA samples.
Based on average of E2F2 and NOTCH2 for 1p 
and PLAUR for 19q, as shown in Tables 1 and 2, our 
CQ-PCR revealed 1p/19q deletion for 57% OTs over-
all (25/44). Deletion of the 1p marker genes were not 
seen in the 14 GBM DNA samples, while deletion 
of the 19q marker gene was found in 8 out 14 (57%) 
GBM samples but not found in the eight OA samples. 
Thus, we did not find co-deletions of 1p and 19q in 
our GBM or OA samples. Deletion of either 1p, or 
19q marker genes were mainly found in OG (48% and 
76%, respectively). Co-deletions of 1p and 19q were 
also mainly found in OG (9/21, 43%), compared with 
AO & AOA combined (only 1 of 15, 7%).
The attempt of this study is to develop a PCR-
based detection of 1p19q deletion for use in predict-
ing  patient’s  outcome.  While  FISH-based  1p19q 
deletion data have being shown with values in prog-
nosis and prediction of radiation and chemotherapy, 
we therefore compared our CQ-PCR-derived data 
with that of FISH. Shown in Table 1, out of 18 DNA 
samples which had 1p19q deletion status available 
by both CQ-PCR and FISH techniques, the concor-
dance rate between the two techniques was 83% 
Figure 1. Real-time CQ-PCR detection of gender information based on 
human dNA samples. Bar and line height are mean (Sd) ratios of dNA 
copy numbers of ERC2 gene in 3p14.3 (open bar) and NLGN4Y gene 
in yq11.221 (filled bar) to three other genes in 8q22.2 (PGCP), 2q34 
(SPAG16), 5q31.2 (SPOCK1), in a male and a female blood dNA.
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N
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(15/18) and 78% (14/18) for 1p and 19q deletions, 
respectively.
Discussion
Our  CQ-PCR  detected  1p  and/or  19q  deletions  in 
majority  of  classical  oligodendroglioma  samples 
(81% of OG and 47% of AO), but in minority of OA 
(13%). These results data consistent with those gen-
erally reported for LOH and FISH assays studying 
these tumor types.3,4,23 In addition, 15 out 18 sam-
ples showed concordant results between FISH and 
CQ-PCR. Considering the small tumor sample size 
and limited marker loci used in our study, such a high 
concordance  is  remarkable,  and  suggests  that  our 
CQ-PCR has the potential to be used to define 1p/19q 
deletion status independent of FISH and LOH analy-
sis. CQ-PCR does not require paired blood samples, 
strong reliance on technical considerations such as 
technician consistency and experience, and is much 
less costly than either LOH or FISH. Thus we could 
use this technology to effectively screen all available 
tumor DNA samples to determine 1p/19q deletion sta-
tus which will aid in building multivariate prognosis 
models for OT. The prognostic and   predictive values 
of CQ-PCR-derived 1p/19q status will be determined 
based on a larger sample size with a large enough 
event number.
Our CQ-PCR finding of no 1p deletions in GBMs 
is  consistent  with  results  reported  with  LOH  and 
FISH.  However,  we  did  detect  PLAUR  deletion 
in19q in 57% of the GBM samples, which has not 
been  previously  recognized.  In  contrast  to  GBM 
samples, none of the 8 OA samples had deletion of 
PLAUR. The identification of gain at 1p marker genes 
CAMTA1, E2F2 and NOTCH2 and 19 q marker gene 
PLAUR was not the focus of this study; however, in 
many OT and GBM samples, gains were detected 
by CQ-PCR that were not evident by FISH. Their 
biological  implications  and  prognostic/predictive 
values on survival and treatment response are yet to 
be determined.
There  have  being  prior  explorations  on 
obtaining  1p/19q  status  based  solely  on  tumor 
DNA. High throughput genomic DNA microarray-
based  technology  known  as  comparative  genomic 
hybridization is able to detect 1p/19q deletions in 
gliomas,  in  addition  to  providing  information  on 
DNA CNV in the entire genome.28,29 It requires well 
Table 2. Frequency of 1p/19 deletions in gliomas.
Histology
 
 
WHO grade 
Tumor number
Glioblatoma 
multiforme (GBM)
 
IV  
n = 14
Anaplastic 
oligodendroglioma 
(AO), anaplastic  
oligo-astrocytoma (AOA) 
III 
n = 15
Oligo-astrocytoma 
(OA)
 
II 
n = 8
Oligodendroglioma 
(OG)
 
II 
n = 21
1p del 0% 14% 13% 48%
19q del 57% 33% 0 76%
Figure 2. Comparison of gene copy number variation between paired dNA samples from patient’s blood and tumor. Bar and line height are mean (Sd) 
ratios of dNA copy numbers of E2F2, NOTCH2, and PLAUR to two reference genes (ERC2 and SPOCK1), quantified by real-time CQ-PCR.
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trained   personnel to not only perform the assay, but 
also  process  the  data;  thus  incurring  high  cost  in 
detecting a few known marker loci. Other PCR-based 
assays  have  also  emerged  including  quantitative 
microsatellite analysis (QUMA)  30,31 and multiplex 
ligation-  dependent  probe  amplification  (MLPA).32 
QUMA  uses  PCR  amplification  of  microsatellite 
loci that contain (CA)n repeats to determine CNV 
of genes of interest, and has also been validated with 
FISH technology on detection of 1p and 19q loss 
in oligodendroglioma.31 However use of primers to 
amplify microsatellite DNA in quantitative PCR can 
be noisy, as multiple lengths of PCR product can be 
produced from cells even with homozygous loci, and 
amplification  efficiency  of  different  microsatellite 
markers  can  be  different,  thus  the  comparability 
between  different  platforms  would  be  challenged. 
MLPA-based detection of 1p/19q has the advantage 
of detecting copy number changes of up to 45 loci in 
one relatively simple PCR based assay but it is semi 
quantitative and has yet to be widely adopted.32
Our real-time CQ-PCR utilizes multi-gene recom-
binant standard DNA to determine the absolute ratio 
of DNA copy numbers between the marker genes 
and multiple reference genes in tumor specimens. 
Both marker and reference genes were selected for 
their locations of interest and single-copy in genome 
with PCR primers designed to avoid amplification 
of  corresponding  pseudogenes  in  genome.  It  has 
advantages offered by QUMA in that all loci are 
informative,  paired  normal  tissue  from  the  same 
patient is not required, and even gain can be dis-
tinguished  from  loss.  In  comparison  to  QUMA, 
which requires accurate input of tumor DNA quan-
tity, result from CQ-PCR is an absolute ratio of two 
gene’s DNA quantity. Thus the result is independent 
of DNA input quantity and the accuracy is ensured 
by the specificity of PCR primers.
Our  results  showed  that  CQ-PCR  is  a  highly 
sensitive test; 100 copy numbers of a specific gene 
were able to be robustly quantified in highly diluted 
DNA samples (0.5 ng/µL). In addition to determine 
loss (here 1p/19q), gain of gene copy numbers, such 
as  EGFR  was  also  be  detected  by  CQ-PCR  (our 
  unpublished data).
Inherited  with  PCR-based  molecular  assay,  this 
technique has the disadvantages that it will not detect 
events  without  causing  an  alteration  of  DNA  copy 
number, such as chromosomal translations, and it relies 
on the stability of reference genes. The former concern 
is not an issue for detecting deletion of 1p/19q, while 
the later has been considered by selecting multiple 
reference genes residing in relatively stable areas of 
genome in specific cancer types, which information is 
based on whole genome comparative analyses. It still 
needs to be empirically validated based on a large 
number of tumor samples. In this study, we have tested 
four candidate reference genes in total 58 gliomas, 
with ERC2, SPOCK1, and/or SPAG16 giving similar 
results for the marker gene on CNV, while not when 
normalized  with  PGCP,  a  reference  gene  selected 
based on stable area of chromosome (data not shown). 
In this study, we have taken average ratios to ERC2, 
SPOCK1, and/or SPAG16 to determine deletion sta-
tus of 1p/19q marker genes. The average (medium) 
of the SDs from different reference ratios for the four 
marker genes is 10%–15% (7%–9%), which verified 
our proper use of the reference genes.
In conclusion, CQ-PCR technology reported here 
could be used to effectively screen all available tumor 
DNA samples to get 1p/19q deletion status. Our prior 
studies of glioma prognosis have revealed a prog-
nostic model for OT with high predictive accuracy 
that explained 63% survival variation with signifi-
cant likelihood ratio P-value = 0.0076.
33 It is yet to be 
determined if the CQ-PCR-detected 1p/19q deletion 
has prognostic value, and furthermore if it improves 
the multivariable OT models we have established with 
combined clinical and gene expression variables.
Abbreviations
CQ-PCR,  real  time  comparative  quantitative  poly-
merase chain reaction; CNV, copy number variations; 
FISH, fluorescence in situ hybridization; LOH, loss 
of heterozygosity.
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